Physician profile
Meredith Ann Bratcher
NPI 1497357305
$2,780.55
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $565 · 2022: $1,293 · 2023: $906 · 2024: $16.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $872 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $872.32 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $579.17 | 2021-2023 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $559.27 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $238.70 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $169.70 | 2022 | |
| Janssen Pharmaceuticals, INC | $159.64 | 2021-2022 | |
| Pfizer INC. | $146.99 | 2022-2023 | |
| Astellas Pharma US INC | $129.10 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $70.48 | 2022 | |
| Sumitomo Pharma America, INC. | $50.73 | 2023 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.65 | 2021-2023 | Jardiance, Synjardy |
| Currax Pharmaceuticals LLC | $50.00 | 2023 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $44.22 | 2021-2022 | |
| Eisai INC. | $39.45 | 2021-2022 | |
| Glaxosmithkline, LLC. | $34.05 | 2023 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $33.06 | 2022-2023 | Farxiga |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Bratcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.